News & Updates
Filter by Specialty:
Prasugrel on par with clopidogrel in reducing stroke recurrence in thrombotic stroke patients
In thrombotic stroke patients at high risk of ischaemic stroke recurrence, prasugrel was as effective as clopidogrel in reducing the composite incidence of ischaemic stroke, MI, and death from other vascular causes, the phase III PRASTRO-III study has shown.
Prasugrel on par with clopidogrel in reducing stroke recurrence in thrombotic stroke patients
11 Nov 2022
KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment
An extended 4.5-year follow-up of the phase III KEYNOTE-240 trial showed that pembrolizumab continued to provide clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), with a manageable safety profile, vs placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC).
KEYNOTE-240 4.5-year follow-up supports pembrolizumab’s role in 2L advanced HCC treatment
11 Nov 2022
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer
10 Nov 2022
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
10 Nov 2022
AF does not reduce dapagliflozin efficacy in HF patients
The presence of atrial fibrillation (AF) at baseline does not appear to modify the benefits of dapagliflozin, compared with placebo, on symptoms and clinical events in patients with heart failure and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), according to a study.
